DDInter624 DDInter1118
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers).
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Quazepam
Quazepam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Arsenic trioxide
Arsenic trioxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Hydrochlorothiazide
Hydrochlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Voriconazole
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Digitoxin
Digitoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is upregulated by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound) and Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Quazepam (Compound) and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Arsenic trioxide (Compound) and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Voriconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Digitoxin (Compound) and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is upregulated by Mycophenolic acid (Compound) and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide